What’s getting funded in longevity right now?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
What’s getting funded in longevity right now? Above all, epigenetic reprogramming programs moving toward human trials, narrower rejuvenation technologies with a clear first indication, and preventive-health platforms that already have paying, returning customers.
The market looks hot, but the capital is heavily concentrated. In our sample of 12 core longevity companies, roughly $950 million was announced since the start of 2025; NewLimit alone represented about 64%, and the top three companies represented about 81%.
The biggest biotech checks are no longer paying only for an ambitious theory of aging. They are increasingly tied to manufacturing scale-up, IND clearance, first-patient dosing and a plausible route to clinical readouts.
Most longevity startups still enter through an ordinary disease. Vision loss, liver dysfunction, muscle degeneration, infertility, metabolic disease and blood cancers give investors endpoints they can understand long before a company can prove that it changed aging itself.
Preventive-health platforms are attracting even larger financings than most longevity drug companies because they can already show demand, retention and customer economics. Neko Health’s $700 million Series C and Function Health’s $298 million Series B plus $450 million growth financing belong to a different business model, even when they sit under the same longevity label.
AI helps when it produces something concrete: a drug target, a better experiment or a licensing deal. Gero, Junevity and Juvenescence are getting credit for what their systems generate, not simply for putting AI at the center of the pitch.
Reproductive longevity and pet longevity are becoming real venture niches because both compress the biological clock. Ovarian aging can be measured within fertility trials, while dogs make health and survival outcomes observable within years rather than decades.
Senolytics have lost their former position as the field’s flagship theme after UNITY Biotechnology’s collapse. The mechanism is still being studied, but new companies now face a much higher burden of proof than reprogramming, regeneration and tissue-specific restoration programs.
Pharma and government money are reinforcing different parts of the market. Drugmakers are paying for targets, biologics and defined programs they can move through normal development, while ARPA-H is funding the endpoints and trial frameworks needed to make healthspan measurable.
The hardest place to raise is the vague middle: a broad “live longer” story without near-term clinical evidence or commercial traction. Longevity is being funded aggressively, but the money is flowing to companies that can turn a huge aging thesis into proof investors can see within a few years.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
What actually counts as a longevity startup today?
Today, longevity funding splits into two businesses that should not be mixed together: companies trying to change the biology of aging, and companies selling preventive-health services that help people stay healthy for longer.
For this article, we treat NewLimit, Life Biosciences, Gero, Juvena Therapeutics, Junevity and similar companies as core longevity biotech because their science directly targets cellular aging, age-related loss of function or mechanisms linked to healthspan. We also include narrower branches such as reproductive aging, pet longevity and biological-age diagnostics when aging itself is central to the product.
Neko Health and Function Health sit in a separate bucket. Both sell prevention rather than age-reversing drugs, yet investors increasingly treat them as part of the same commercial longevity story. That distinction changes the answer quite a lot. A rejuvenation-drug round and a giant preventive-health round may both appear in “longevity funding,” even though investors are making completely different bets.
Is longevity funding actually booming right now?
Longevity funding is hot at the top right now, but a small number of companies account for most of the money.
We manually checked a sample of 12 longevity-focused companies with publicly disclosed financings since the start of 2025, excluding broad preventive-health platforms such as Neko Health and Function Health and excluding grants from the venture total. Those companies announced roughly $950 million of financing.
NewLimit accounts for about $610 million of that sample through its $130 million Series B, a $45 million follow-on financing and a $435 million Series C. That is roughly 64% of the entire amount. Add Life Biosciences’ $80 million Series D and Juvenescence’s $76 million first Series B-1 close, and three companies account for about 81% of the capital we tracked.
The longevity market can support huge rounds right now. Most companies are nowhere near them. The other financings we found generally sit between roughly $6 million and $44 million, which shows how selectively investors are backing platforms they believe can cross into the clinic.
| Company | Recent disclosed financing we counted | Main longevity angle |
|---|---|---|
| NewLimit | $610M across three financings | Epigenetic reprogramming |
| Life Biosciences | $80M Series D | Partial epigenetic reprogramming |
| Juvenescence | $76M first Series B-1 close | Age-related therapeutics |
| Gameto | $44M Series C | Reproductive aging |
| Juvena Therapeutics | $33.5M Series B | Regenerative biologics |
| Loyal | $22M B-2 | Canine longevity |
| Rapalogix Health | $20M Series A | Skin-aging biology |
| Junevity | $20M total seed financing | Cell-reset therapeutics |
If you want more recent data on this point, please see our latest longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
What longevity biotech is getting the biggest checks right now?
Epigenetic reprogramming is getting the biggest checks in core longevity biotech by a wide margin.
NewLimit’s $435 million Series C is the clearest example. The company says its lead program can restore younger function in old human liver cells and is being prepared for human testing. The round valued NewLimit at about $3.1 billion and followed two earlier financings totaling $175 million.
Life Biosciences raised $80 million for a partial-reprogramming program that has already moved into humans. Its ER-100 therapy uses three reprogramming factors and is being tested first in optic neuropathies; the company announced that the first patient had been dosed in 2026.
Retro Biosciences adds another large valuation marker even though it did not disclose the size of its latest financing. Retro announced an initial close at a $1.8 billion pre-money valuation while running a Phase 1 trial and developing tissue-reprogramming programs alongside other approaches.
The gap is huge. Seed rounds around $10 million remain common elsewhere in longevity, while leading reprogramming companies are being financed more like well-capitalized late-stage biotech.
Why are investors putting so much money into epigenetic reprogramming?
Investors are paying up for epigenetic reprogramming because the science has moved from “can old cells look younger?” toward “can we turn this into a drug and test it in people?”
A few years ago, reprogramming companies were financed mainly around a powerful biological idea: cell state might be reversible. The newer rounds are attached to much more concrete milestones. NewLimit says it found a prototype medicine early enough to bring its first program toward clinical trials in 2027. Its latest progress update also reported a 100-fold manufacturing scale-up of the lead therapeutic asset and additional payloads that restored function in old hepatocytes and endothelial cells.
Life Biosciences has gone further. After FDA clearance of its IND, the company started the Phase 1 trial of ER-100 and later confirmed that the first patient had been dosed. The $80 million Series D is funding a human study, not another open-ended discovery cycle.
That is why the checks have grown. Reprogramming still carries enormous biological and safety risk, especially around cell identity, delivery and uncontrolled growth, but investors can now attach their money to manufacturing, IND work, first dosing and clinical readouts. Those are milestones biotech investors know how to price.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Can a pure anti-aging moonshot still raise big money today?
Yes, a pure anti-aging moonshot can still raise big money today, but investors increasingly want evidence that the moonshot can produce conventional medicines.
Retro Biosciences is probably the cleanest example. The company still states an unusually ambitious goal of adding ten healthy years to human lifespan, and its latest financing came at a $1.8 billion pre-money valuation. Yet Retro already has RTR242 in Phase 1 for Alzheimer’s disease and says the program went from indication selection to first-in-human dosing in about 15 months.
That puts Retro in a very different position from a research company asking investors to finance aging science indefinitely. It can keep tissue reprogramming, cell therapy and other long-horizon programs under the same roof while an ordinary clinical candidate generates human data.
UNITY Biotechnology is the warning investors remember. Once one of the best-known senolytics companies, it stopped clinical development and formally dissolved in 2025 after its programs failed to create enough value to finance the company. The lesson was blunt: the audacious mission can stay, but there has to be a credible path to a drug.
Why do longevity startups keep starting with one normal disease?
Longevity startups use specific diseases as the fastest route to prove that aging biology can become medicine.
Junevity is building “cell reset” therapies around transcription factors linked to damaged cell states, but its first programs are aimed at obesity, type 2 diabetes and frailty. HexemBio talks explicitly about rejuvenating aged blood stem cells, while its first clinical route is bone-marrow transplantation for blood cancers. Nula Therapeutics is studying multi-system rejuvenation through estrogen-receptor biology, yet its development plan gives investigators measurable metabolic and functional outcomes rather than asking whether a participant simply “aged more slowly.”
Later-stage companies make the same choice. Gameto’s broader science is about ovarian aging, while Fertilo gives the company a concrete IVF product and a Phase 3 trial. Loyal wants to alter biological aging in dogs, but its regulatory work centers on defined drug candidates with FDA requirements for effectiveness, safety and manufacturing.
This makes the first experiment much easier to finance. A startup can test a mechanism within a few years, use endpoints regulators already understand and preserve the larger healthspan thesis for later. Investors get a nearer read on whether the biology works.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Is AI actually helping longevity startups raise money?
AI is helping longevity startups raise money, but the strongest cases use it to produce drug targets or better experiments rather than selling AI as the product.
Gero recently raised $17 million, bringing its total equity financing to $34 million. The more interesting number sits outside the venture round: Chugai, part of the Roche Group, signed a research and licensing agreement around targets found through Gero’s aging-focused AI platform, with up to roughly $250 million in potential development and sales milestones plus royalties.
Juvenescence raised $76 million in its first Series B-1 close and then acquired Ro5, whose biomedical knowledge graph contains more than 85 million nodes and roughly 400 million relationships. The acquisition gives Juvenescence an internal system for selecting targets and designing compounds across cognition, cardio-metabolism, immunity and cellular repair.
Junevity offers a smaller early-stage version of the same idea. Its RESET platform uses large human datasets and machine learning to identify transcription factors that may restore damaged cell states; the company doubled its seed financing to $20 million after advancing its lead programs.
Across these companies, AI earns credibility when it changes the drug-development process. Investors still have to believe the target, molecule or experiment that comes out the other end.
What other longevity technologies are investors funding besides reprogramming?
Investors are funding several narrower forms of rejuvenation, especially when a company can point to one tissue, one pathway or one product it can test relatively soon.
Juvena Therapeutics raised $33.5 million for regenerative biologics designed to restore tissue function, with a lead program focused on muscle disease. HexemBio raised $10.4 million to develop a system that rejuvenates a patient’s own aged blood stem cells outside the body before reinfusion. Remedium Bio has announced the initial close of a planned $10 million Series A, led by Lifespan Vision Ventures with participation from Eli Lilly, to turn adipose cells into durable producers of therapeutic proteins.
Rapalogix Health shows how far the category can stretch commercially. Its $20 million Series A funds both the expansion of an already launched professional skincare product and development of RLX-202, a selective mTORC1 inhibitor for dermatology. The company is using longevity biology in a market where consumers already spend heavily on aging, while keeping a prescription-drug pipeline behind it.
These rounds are far smaller than the largest reprogramming financings, but they show a broader preference. Investors are more comfortable funding rejuvenation when a company defines exactly which cells or tissue it intends to restore and how that restoration will be measured.
| Approach | Recent company example | Financing | First thing it can test or sell |
|---|---|---|---|
| Regenerative biologics | Juvena Therapeutics | $33.5M | Muscle degeneration |
| Blood stem-cell rejuvenation | HexemBio | $10.4M | Bone-marrow transplantation |
| Durable protein expression | Remedium Bio | Planned $10M Series A | Chronic-disease therapeutics |
| mTORC1 / skin longevity | Rapalogix Health | $20M | Dermatology and professional skincare |
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Have investors moved on from senolytics?
Senolytics have clearly lost their place as the flagship longevity investment theme, while capital has shifted toward reprogramming, regeneration and other ways to restore cell function.
UNITY Biotechnology changed the tone. The company was built around clearing senescent cells and became one of the public faces of longevity biotech, yet its clinical programs repeatedly struggled to produce enough benefit. After shutting down development and exhausting financing alternatives, UNITY filed for dissolution in 2025.
Senescence research continues, so it would be wrong to declare the mechanism disproved. The burden of proof has changed. A new senolytics company now enters a market that has already watched a well-funded pioneer fail.
Autophagy has recently gained more practical credibility. Retro Biosciences moved RTR242, an oral program intended to improve cellular recycling, into Phase 1 for Alzheimer’s disease. Retro’s pipeline still lists RTR242 in Phase 1, and a full public readout has yet to appear. Rapalogix is working on selective mTORC1 inhibition in skin. Investors still fund classic aging pathways, but the programs getting attention now tend to arrive with a specific drug, tissue and clinical route attached.
If you want more recent data on this point, please see our latest longevity market report.
Is reproductive longevity becoming a real venture category?
Reproductive longevity has become a real venture category, with ovarian aging giving investors a much faster way to measure whether age-related biology can be changed.
Gameto raised a $44 million Series C, bringing its announced total funding to $127 million, to complete late-stage development of Fertilo. The technology uses stem-cell-derived ovarian support cells to mature eggs outside the body, reducing the amount of hormonal stimulation normally needed during IVF.
The attraction goes beyond fertility. Ovarian function declines much earlier than most other human systems, giving researchers a compressed and visible model of biological aging. Menopause, fertility, hormone production and ovarian reserve also create several possible commercial markets around the same underlying biology.
The category still overlaps heavily with women’s health and reproductive biotech, so calling every fertility company a longevity startup would be misleading. Gameto belongs here because the company explicitly builds around ovarian aging and cell engineering. That combination of a large existing market and an aging mechanism that can be measured within clinical-trial timelines makes reproductive longevity easier to finance than many whole-body lifespan ideas.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Are biological-age tests getting funded, or is the bigger money going to preventive health?
Biological-age tests are getting funded, but preventive-health platforms with recurring customers are attracting far larger checks.
Generation Lab raised an $11 million seed round for SystemAge, a blood-based test designed to estimate aging across multiple organ systems. The company says the product has reached hundreds of clinics and later released separate female and male versions of its test.
The funding scale changes once measurement becomes part of a broader health service. Neko Health raised a $700 million Series C after previously raising $260 million. The company says more than 100,000 people have completed its preventive scan in Europe, more than 350,000 people have registered or joined the waitlist, and roughly 75% of members book and prepay the following year’s scan. Neko is now moving into the United States, with 25,000 people already on the New York waitlist.
Function Health has followed a different route with lab testing, imaging and medical interpretation. After a $298 million Series B, Function secured $450 million from General Catalyst’s Customer Value Fund. That latest financing is tied to customer acquisition and customer economics rather than functioning like a normal valuation-setting equity round. Function says it now has more than 500,000 members.
For investors, the difference is obvious. A biological-age test has to prove that the number it generates is useful. Neko and Function can already show whether people pay, return and buy more services. That is why investors are willing to put much more money behind the broader preventive-health platforms.
| Company | Recent financing | What investors can already measure |
|---|---|---|
| Generation Lab | $11M seed | Clinic adoption of a biological-age test |
| Neko Health | $700M Series C | 100,000+ scans, 350,000+ registrations or waitlist entries, and repeat bookings |
| Function Health | $298M Series B plus $450M growth financing | 500,000+ members and customer economics |
If you want more recent data on this point, please see our latest longevity market report.
Is pet longevity becoming a serious venture market?
Pet longevity is becoming a serious niche because dogs let investors test aging interventions on a much shorter timeline than humans.
Loyal raised another $22 million alongside an FDA milestone for LOY-002, a drug intended to extend healthy lifespan in senior dogs. Its STAY study enrolled more than 1,000 dogs across veterinary clinics, giving the company a direct way to test health and survival outcomes within years rather than decades.
Rejuvenate Bio offers a second model. The company raised $6 million and entered an R&D collaboration with Merck Animal Health around gene therapy for companion animals. Rejuvenate ultimately has ambitions in age-related disease beyond pets, but veterinary development gives the platform a nearer commercial market and a faster biological clock.
The economics are still small beside human medicine, yet the strategic value can be larger than the market size suggests. A successful canine longevity drug would show regulators, drug developers and consumers that lifespan itself can become a pharmaceutical endpoint in a mammal people live with every day.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Are big pharma companies actually investing in longevity now?
Big pharma is putting real money and technical resources into longevity, although the deals still center on specific drugs and targets rather than a broad “anti-aging” franchise.
Chugai’s agreement with Gero carries up to roughly $250 million in potential milestones plus royalties and gives Chugai rights to develop antibodies against targets identified by Gero. Eli Lilly participated in Juvena Therapeutics’ Series B after signing a muscle-health research collaboration that could be worth more than $650 million if all milestones are reached.
Lilly also joined Remedium Bio’s latest Series A financing. Merck Animal Health participated in Rejuvenate Bio’s $6 million round while signing an R&D collaboration with the company.
With Chugai, Lilly and Merck all involved, longevity has moved beyond occasional industry curiosity. Pharma companies are engaging when the science produces something they can plug into normal drug development: a target, a biologic, a gene therapy or a defined disease program. Broad revenue plans built around treating aging itself still have not appeared.
Is government funding changing what longevity startups can build?
Government funding is starting to push longevity research toward one problem private investors have little incentive to solve alone: proving healthspan in a way regulators can accept.
ARPA-H’s PROSPR program funds projects designed to extend healthy function and build the tools needed to measure it. Nula Therapeutics received an award of up to $20 million to test whether modulating estrogen-receptor biology can improve multi-system aging outcomes. Transposon Therapeutics received up to $22 million to study TPN-101 in healthy aging. Other PROSPR awards support work on biomarkers, trial design and interventions that can be evaluated across several body systems.
This is unusually useful for the startup market. A conventional biotech company can normally borrow an established endpoint such as tumor shrinkage, LDL cholesterol or seizure frequency. Longevity companies often have to prove that their intervention affects a slower, multi-system process for which the regulatory playbook remains incomplete.
Public programs can pay for some of the tools the whole field needs. If PROSPR produces practical endpoints and trial designs, future startups will have an easier time showing investors what a successful aging trial actually looks like.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
So what’s getting funded in longevity right now?
Right now, longevity money is concentrating around companies that can turn a huge aging thesis into evidence investors can see within a few years.
At the biotech end, epigenetic reprogramming has the strongest financing momentum. The biggest checks are going to companies moving cellular rejuvenation toward human trials, while smaller but meaningful rounds are supporting tissue regeneration, blood-stem-cell rejuvenation, mTOR biology, reproductive aging, AI-discovered targets and other mechanisms with clear first applications.
The second pool of money is even more commercial. Preventive-health companies such as Neko Health and Function Health are raising at a scale most longevity drug startups cannot approach because investors can already measure demand, retention and expansion. The product may promise healthier years rather than biological age reversal, but customers can buy it today.
The market has become less forgiving of aging science that cannot show where the first clinical proof will come from. UNITY’s collapse still hangs over senolytics, while newer companies increasingly enter through liver disease, vision loss, muscle degeneration, fertility, blood cancers, metabolic dysfunction or animal health.
Longevity is getting funded aggressively, and the money is much more selective than the headline totals suggest. Investors are backing radical aging biology when it has a believable route into the clinic, and they are backing preventive longevity when customer behavior already proves there is a business. The vague middle — a broad “live longer” story with neither clinical evidence nor real commercial traction — is currently the hardest place to raise.
If you want more recent data on this point, please see our latest longevity market report.
OUR METHODOLOGY
This analysis asks what is actually attracting capital across longevity today. We separate core longevity biotech from preventive-health platforms because a round for a cellular-rejuvenation program and a round for a recurring diagnostic service reflect different scientific risks, business models and investor expectations.
For the venture-funding comparison, we manually reviewed a sample of 12 longevity-focused companies with publicly disclosed financings announced since the start of 2025. We included companies whose product directly targets aging biology, age-related loss of function or a closely defined branch such as reproductive aging, pet longevity or biological-age diagnostics. Broad preventive-health platforms were analyzed separately, and government grants were excluded from the roughly $950 million venture total.
We counted disclosed equity financings, follow-on rounds and announced first closes at their stated values. Undisclosed financings were not estimated. We also kept valuation markers, pharmaceutical milestone payments, public awards and customer-acquisition financing separate from ordinary venture rounds so that unlike forms of capital did not inflate the same total.
We then compared the market across several dimensions: where the largest rounds are clustering, how close each scientific platform is to human testing, which disease or product provides the first proof point, whether AI produces targets or partnerships, how much commercial traction preventive platforms can show, and where pharma or government funding is filling a gap private venture capital may not cover.
Setbacks were used to interpret changing investor expectations, not to declare an entire mechanism dead. UNITY Biotechnology’s dissolution is relevant because it raised the burden of proof for new senolytics companies; it does not show that every approach to cellular senescence has failed.
We prioritized company financing announcements, clinical and regulatory updates, pharmaceutical-partner disclosures and government documents. Customer counts, waitlists and renewal figures were treated as company-reported commercial evidence, while contingent partnership milestones were treated as potential deal value rather than cash already received.
Key sources include NewLimit’s $435 million Series C announcement and its 2026 scientific and manufacturing update; Life Biosciences’ $80 million Series D announcement, ER-100 IND clearance and first-patient dosing update; Retro Biosciences’ 2026 financing update; Chugai’s Gero research and licensing agreement; Junevity’s financing and program updates; Generation Lab’s SystemAge financing announcement; Gameto’s Series C announcement; Neko Health’s $700 million Series C announcement; Function Health’s Series B announcement and financing announcement archive; Loyal’s veterinary product brief; and ARPA-H’s PROSPR program materials together with its healthspan-regulatory framework work.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- What does the longevity startup landscape look like today?
